מיפג'ין

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

MIFEPRISTONE

Disponibbli minn:

A. LAPIDOT PHARMACEUTICALS, LTD

Kodiċi ATC:

G03XB01

Għamla farmaċewtika:

טבליה

Kompożizzjoni:

MIFEPRISTONE 200 MG

Rotta amministrattiva:

פומי

Tip ta 'preskrizzjoni:

מרשם נדרש

Manifatturat minn:

EXELGYNE LABORATORIES, FRANCE

Grupp terapewtiku:

MIFEPRISTONE

Żona terapewtika:

MIFEPRISTONE

Indikazzjonijiet terapewtiċi:

Medical alternative to uterine suction for termination of intra-utrerine Pregnancy: - up to and no later than 49 days of amenorrhea (seven weeks) - in sequential use with a prostaglandin analogue misoprostol 400 mcg per os administered 36 to 48 hours after Mifegyne intake. Under these conditions the association of mifepristone and prostaglandins leads to a success rate of about 95 per cent of the cases. Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reason (beyond the first trimester). Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.

Data ta 'l-awtorizzazzjoni:

2014-07-31